


A Study of Pharmaceutical Supply Dynamics for People with Type 1 Diabetes in Ukraine During Martial Law



PRESENTER:
Iryna Vlasenko

BACKGROUND:

The prevalence of diabetes in Ukraine is 8%, with approximately 200,000 people living with type 1 diabetes (PWT1D) who require insulin therapy. Since 2022, Ukraine’s healthcare system has been operating under martial law. The ongoing humanitarian crisis has significantly impacted the delivery of medical and pharmaceutical care to PWT1D and has made access to treatment unpredictable. A reimbursement system for medications was introduced in Ukraine in 2016 and continues to operate despite Russia's full-scale invasion.

THE PURPOSE of work was to study the changes in the provision of care for PWT1D under martial law in Ukraine, introduced on February 24, 2022.

METHODS

The regulatory framework related to the treatment of PWT1D was reviewed. Quantitative analysis which included quantitative indicators (the number of products, number of manufacturers, and changes in the availability of specific drug forms (pen), distribution across therapeutic groups) and comparative methods were used. The objects of the study were insulin products and glucose monitoring supplies.

Despite the ongoing war, Ukraine continues to maintain a functioning reimbursement system that includes a variety of insulin products, ensuring continuity of prescribed therapy for PWT1D. The recent inclusion of test strips in the reimbursement program highlights that the treatment of PWT1D remains a priority for the Ministry of Health of Ukraine.



Glucometers for which reimbursed test strips in Ukraine

Glucometer models	Manufacturer, country
Акку-Чек ІНСТАНТ	«Roche Diabetes Care GmbH», Germany
CONTOUR PLUS	Ascensia Diabetes Care, Switzerland
Oh'Care Lite	OSANG Healthcare Co., Ltd., South Korea
Rightest GS300	BIONIME CORPORATION, Taiwan
Rightest ELSA	
2B ULTRA	Jiangxi AICARE Medical Technology Co., Ltd., China
2BComfort	
Gamma Diamond Voice	TaiDoc Technology Corporation, Taiwan
Gamma Diamond PRIMA	
Gamma Mini	
Gamma Speaker	
NewMed VISIO	NEWMED Гм6Х, Austria
Element	Infopia, South Korea
Finetest Auto-coding premium	
Gluco Dr. Auto AGM-513	All Medicus Co., Ltd, South Korea
Gluco Dr. Auto AGM-4000	
IME-DC	IME-DC GmbH, Germany
On Call Extra, On Call® Plus, ON-CALL EZ.	ACON Laboratories, Inc., USA
OneTouch Select Plus Simple	LifeScan Europe GmbH, Switzerland
OneTouch Ultra Plus Flex	
Wellion Luna Trio	MED TRUST Handelsges.m.b.H., Austria
Longevita Family	RESC GmbH, Austria /
Longevita Smart	Network Selects, China

Insulins subject to reimbursement in Ukraine (2025)		
International Nonproprietary Name	Trade name	Manufacturer
A10AB - Insulins and analogues for injection, fast-acting		
insulin aspart	NovoRapid FlexPen	Novo Nordisk, Denmark
insulin glulisine	APIDRA®	Aventis Pharma Deutschland GmbH, Germany
insulin human	ACTRAPID® HM	Novo Nordisk, Denmark
	ACTRAPID® HMFlexPen	Novo Nordisk, Denmark
	GENSULIN P	BIOTON S.A., Poland
	FARMASULIN® H	JSC «Farmak»
	HUMODAR R 100R	PrJSC “Indar”
A10AC Insulins and analogues for injection, intermediate-acting		
insulin human	PROTAPHANE®	Novo Nordisk, Denmark
	PROTAPHANE® HM FLEXPEN®	Novo Nordisk, Denmark
	GENSULIN N	BIOTON S.A., Poland
	FARMASULIN® H NP	JSC «Farmak»
	HUMODAR B 100R	PrJSC “Indar”
A10AE - Insulins and analogues for injection, long-acting		
insulin glargine 100 U/ml	LANTUS® SoloStar®	Sanofi-Aventis Deutschland GmbH., Germany
	ILAR®	Biocon Biologics India Limited, India/ JSC «Farmak»
insulin glargine 300 U/ml	Toujeo® SoloStar®	Sanofi-Aventis Deutschland GmbH., Germany
insulin detemir	LEVEMIR® FLEXPEN®	Novo Nordisk, Denmark
insulin degludec	TRESIBA® FLEXTOUCH	Novo Nordisk, Denmark
A10AD - Insulins and analogues for injection, intermediate- or long-acting combined with fast-acting		
degludec+ liraglutide	Xultophy	Novo Nordisk, Denmark
glargine + lixisenatide human	SOLIQUA	SANOFI-AVENTIS DEUTSCHLAND, GmbH, Germany
	MIXTARD® 30 HM	Novo Nordisk, Denmark
	MIXTARD® 30 HM FlexPen	Novo Nordisk, Denmark
	GENSULIN M 30	BIOTON S.A., Poland.
	FARMASULIN® H 30/70	JSC «Farmak»
	HUMODAR C 25 100R	PrJSC “Indar”
aspart	NovoMix ® 30 FlexPen	Novo Nordisk, Denmark
degludec+ aspart	Rayzodeg ® FlexTouch	Novo Nordisk, Denmark



RESULTS

The Ministry of Health of Ukraine updated the Clinical Guideline “Type 1 Diabetes Mellitus in Adults” in 2023. A comparative analysis revealed a decrease in the number of insulin products included in the reimbursement list — from 31 in 2021 to 26 in 2025. Notably, insulin lispro and its combinations are no longer included in the 2025 reimbursement list. Currently, 33.3% of reimbursed insulin products are manufactured in Ukraine. There has also been an increase in the availability of insulin in pen form. In 2023, 24 types of test strips for self-monitoring—compatible with 25 different glucometers—were added to the reimbursement program for PWT1D.

DISCUSSION

The current reimbursement system in Ukraine includes a wide range of insulins, including analogues and combinations (glargine with lixisenatide; degludec with liraglutide; degludec with aspart). A stable insulin market helps minimize the risk of unnecessary switching to alternative insulin types. The inclusion of test strips for PWT1D in the reimbursement system is a positive development that supports better self-monitoring and maybe reduces the risk of complications. This approach should also be extended to patients with type 2 diabetes.

Iryna Vlasenko author